Broadening the repertoire of melanoma-associated T-cell epitopes

Cancer Immunology, Immunotherapy

Volumn 64, Issue 5, 2015, Pages 609-620

  Frøsig, Thomas Mørch ^a,b,c   Lyngaa, Rikke ^a,c   Met, Özcan ^a   Larsen, Stine Kiær ^a   Donia, Marco ^a   Svane, Inge Marie ^a   thor Straten, Per ^a   Hadrup, Sine Reker ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

Combinatorial encoding; HLA A2 negative; Melanoma; MHC multimer; T cell epitope mapping

Indexed keywords

DOPACHROME TAUTOMERASE; GLYCOPROTEIN GP 100; HLA A1 ANTIGEN; HLA A11 ANTIGEN; HLA A3 ANTIGEN; HLA B7 ANTIGEN; MELAN A; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE; NY ESO 1 ANTIGEN; EPITOPE; HLA ANTIGEN; MELANOMA ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; BLOOD; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN CELL; IC50; IMMUNOREACTIVITY; IN VITRO STUDY; K562 CELL LINE; LIMIT OF DETECTION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA CELL LINE; METASTATIC MELANOMA; PEPTIDE LIBRARY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN LOCALIZATION; T CELL CULTURE; TARGET CELL; TUMOR ASSOCIATED LEUKOCYTE; ADOPTIVE IMMUNOTHERAPY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; MELANOMA; MONONUCLEAR CELL; PEPTIDE MAPPING; TRANSPLANTATION; TUMOR CELL LINE;

CELL LINE, TUMOR; EPITOPES, T-LYMPHOCYTE; HLA ANTIGENS; HLA-A1 ANTIGEN; HLA-A11 ANTIGEN; HLA-A3 ANTIGEN; HLA-B7 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; MELANOMA-SPECIFIC ANTIGENS; PEPTIDE MAPPING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84938415245     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1664-x     Document Type: Article

References (48)

1. Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
2. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
3. Hamid O, Robert C, Daud A et al (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144
4. Brahmer JR, Tykodi SS, Chow LQM et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465
5. Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133
6. Rosenberg SA, Yang JC, Sherry RM et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550–4557
7. Hinrichs CS, Rosenberg SA (2014) Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 257:56–71
8. Besser MJ, Shapira-Frommer R, Itzhaki O et al (2013) Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res 19:4792–4800
9. Ellebaek E, Iversen TZ, Junker N et al (2012) Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med 10:169
10. Radvanyi LG, Bernatchez C, Zhang M et al (2012) Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18:6758–6770
11. Andersen RS, Thrue CA, Junker N et al (2012) Dissection of T-cell antigen specificity in human melanoma. Cancer Res 72:1642–1650
12. Kvistborg P, Shu CJ, Heemskerk B et al (2012) TIL therapy broadens the tumor-reactive CD8(+) T-cell compartment in melanoma patients. Oncoimmunology 1:409–418
13. Hoashi T, Tamaki K, Hearing VJ (2010) The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding. FASEB J 24:916–930
14. Solano F, Briganti S, Picardo M, Ghanem G (2006) Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res 19:550–571
15. Jackson IJ, Chambers DM, Tsukamoto K et al (1992) A second tyrosinase-related protein, TRP-2, maps to and is mutated at the mouse slaty locus. EMBO J 11:527–535
16. Hoashi T, Watabe H, Muller J et al (2005) MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. J Biol Chem 280:14006–14016
17. Aung PP, Liu Y-C, Ballester LY et al (2014) Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. Hum Pathol 45:259–267
18. Boyle JL, Haupt HM, Stern JB, Multhaupt HAB (2002) Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors. Arch Pathol Lab Med 126:816–822
19. Takeuchi H, Kuo C, Morton DL et al (2003) Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res 63:441–448
20. Goydos JS, Patel M, Shih W (2001) NY-ESO-1 and CTp11 expression may correlate with stage of progression in melanoma. J Surg Res 98:76–80
21. Roeder C, Schuler-Thurner B, Berchtold S et al (2005) MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch Dermatol Res 296:314–319
22. Hadrup SR, Toebes M, Rodenko B et al (2009) High-throughput T-cell epitope discovery through MHC peptide exchange. Methods Mol Biol 524:383–405
23. Toebes M, Coccoris M, Bins A et al (2006) Design and use of conditional MHC class I ligands. Nat Med 12:246–251
24. Bakker AH, Hoppes R, Linnemann C et al (2008) Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proc Natl Acad Sci USA 105:3825–3830
25. Rodenko B, Toebes M, Hadrup SR et al (2006) Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc 1:1120–1132
26. Hadrup SR, Bakker AH, Shu CJ et al (2009) Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 6:520–526
27. Andersen RS, Kvistborg P, Frøsig TM et al (2012) Parallel detection of antigen-specific T-cell responses by combinatorial encoding of MHC multimers. Nat Protoc 7:891–902
28. Hombrink P, Hadrup SR, Bakker A et al (2011) High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS One 6:e22523
29. Lyngaa R, Pedersen NW, Schrama D et al (2014) T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish merkel cell carcinoma patients from healthy donors. Clin Cancer Res 20(7):1768–1778
30. Nielsen M, Lundegaard C, Worning P et al (2003) Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 12:1007–1017
31. Lundegaard C, Lamberth K, Harndahl M et al (2008) NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res 36:W509–W512
32. Lundegaard C, Lund O, Nielsen M (2008) Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers. Bioinformatics 24:1397–1398
33. Hoof I, Peters B, Sidney J et al (2009) NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 61:1–13
34. Nielsen M, Lundegaard C, Blicher T et al (2007) NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One 2:e796
35. Day CL, Seth NP, Lucas M et al (2003) Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 112:831–842
36. Met O, Svane IM (2013) Analysis of survivin-specific T cells in breast cancer patients using human DCs engineered with survivin mRNA. Methods Mol Biol 969:275–292
37. Stanke J, Hoffmann C, Erben U et al (2010) A flow cytometry-based assay to assess minute frequencies of CD8+ T cells by their cytolytic function. J Immunol Methods 360:56–65
38. Donia M, Junker N, Ellebaek E et al (2011) Characterization and comparison of “Standard” and “Young” tumor infiltrating lymphocytes for adoptive cell therapy at a Danish Translational Research Institution. Scand J Immunol 75:157–167
39. Kawakami Y, Robbins PF, Wang X et al (1998) Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol 161:6985–6992
40. Pittet MJ, Valmori D, Dunbar PR et al (1999) High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190:705–715
41. Visseren MJ, van Elsas A, van der Voort EI et al (1995) CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 154:3991–3998
42. Benlalam H, Linard B, Guilloux Y et al (2003) Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J Immunol 171:6283–6289
43. Romero P, Valmori D, Pittet MJ et al (2002) Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma. Immunol Rev 188:81–96
44. Larrieu P, Renaud V, Godet Y et al (2008) A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes. Cancer Immunol Immunother 57:745–752
45. Bettinotti MP, Kim CJ, Lee KH et al (1998) Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J Immunol 161:877–889
46. Dutoit V, Rubio-Godoy V, Pittet MJ et al (2002) Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans. J Exp Med 196:207–216
47. Pinto S, Sommermeyer D, Michel C et al (2014) Mis-initiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T-cells. Eur J Immunol 44(9):2811–2821
48. Donia M, Hansen M, Sendrup SL et al (2013) Methods to improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion. J Invest Dermatol 133:545–552